The Next Generation of Weight Loss Medications
Retatrutide is an investigational medication from Eli Lilly that has drawn attention for its impressive weight loss results in clinical trials. But it's not available yet—and it's important to understand where it stands.
How Is Retatrutide Different?
Current medications target one or two hormones:
- Semaglutide: GLP-1
- Tirzepatide: GLP-1 and GIP
Retatrutide targets three hormones: GLP-1, GIP, and glucagon. The glucagon component is thought to increase energy expenditure and help reduce liver fat, potentially adding to the effects of appetite reduction.
What Do Trials Show?
In the phase 3 TRIUMPH-1 trial, participants taking the highest dose of retatrutide lost an average of about 28% of their body weight over 80 weeks in the main efficacy analysis—among the largest average weight loss results reported for a medication.
Side effects were similar to other drugs in this class, mainly nausea, diarrhea, and vomiting, especially during dose increases.
When Will It Be Available?
As of late 2026, retatrutide is not FDA-approved. Eli Lilly has said it plans to submit it for FDA approval in early 2027. After submission, FDA review typically takes about a year, though timelines can vary.
A Word of Caution
Products sold online as "retatrutide" are not approved, not regulated, and may not contain what they claim. Unapproved versions can be contaminated, mislabeled, or incorrectly dosed. Using them carries real safety risks.
What You Can Do Now
Approved medications like semaglutide and tirzepatide are highly effective for many people today. Combined with nutrition, strength training, and medical support, they can produce meaningful, lasting results.
Learn more about provider-guided weight loss options here: Heva Weight Loss
The Bottom Line
Retatrutide is a promising triple-hormone medication with strong trial results, but it isn't approved yet. FDA submission is expected in 2027. In the meantime, effective approved options are available.